roxadustat + Darbepoetin alfa
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hemodialysis Chronic Kidney Disease Patients With Anemia
Conditions
Hemodialysis Chronic Kidney Disease Patients With Anemia
Trial Timeline
Nov 30, 2016 → Mar 15, 2018
NCT ID
NCT02952092About roxadustat + Darbepoetin alfa
roxadustat + Darbepoetin alfa is a phase 3 stage product being developed by Astellas Pharma for Hemodialysis Chronic Kidney Disease Patients With Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02952092. Target conditions include Hemodialysis Chronic Kidney Disease Patients With Anemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02952092 | Phase 3 | Completed |
| NCT02021318 | Phase 3 | Completed |
| NCT01888445 | Phase 2 | Completed |
Competing Products
20 competing products in Hemodialysis Chronic Kidney Disease Patients With Anemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| ASP7991 | Astellas Pharma | Phase 1 | 33 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| ASP1585 | Astellas Pharma | Phase 2 | 52 |
| Kiklin capsules | Astellas Pharma | Pre-clinical | 23 |
| Doravirine | Merck | Approved | 85 |
| BPS804 + Placebo | Novartis | Phase 2 | 52 |
| PA21 + Sevelamer hydrochloride | Kissei Pharmaceutical | Phase 3 | 76 |
| PA21 + PA21 + PA21 + PA21 + Placebo | Kissei Pharmaceutical | Phase 2 | 51 |
| PA21 | Kissei Pharmaceutical | Phase 3 | 76 |
| PA21 | Kissei Pharmaceutical | Phase 3 | 76 |
| [¹⁴C]Etelcalcetide | Amgen | Phase 1 | 32 |
| Epoetin Hospira | Pfizer | Phase 3 | 76 |
| Epoetin Hospira | Pfizer | Phase 3 | 76 |
| sodium thiosulfate | Sanofi | Pre-clinical | 22 |
| Enoxaparine | Sanofi | Approved | 84 |
| Alirocumab 150 MG/ML [Praluent] | Regeneron Pharmaceuticals | Phase 3 | 76 |